Category: Raymond
-
Gilead Sciences stock upgraded by Raymond James on strong growth outlook for new drugs By Investing.com
•
On Monday, Raymond James changed its stance on Gilead Sciences Inc. (NASDAQ:GIL) stock, upgrading it from “market perform” to “outperform.” The firm also set a $93.00 price target for the biopharmaceutical company. This update is bolstered by promising data from the PURPOSE-1 study of lenacapavir, a long-acting HIV pre-exposure prophylaxis…
-
WideOpenWest cut to underperform at Raymond James By Investing.com
•
Raymond James downgraded WideOpenWest (WOW) to Underperform, citing limited upside potential following the proposed acquisition. The company received a non-binding offer of $4.80 per share from its major shareholders and affiliates, which is in line with Raymond James’ previous target price of $5. However, the stock is currently trading above…